Importantly, recent studies revealed that AKT inhibitor MK2206 significantly increases the sensitivity of HCC cells to sorafenib in vitro [12], and similarly, the inhibition of AKT signaling can sensitize HCC to Lenvatinib treatment [19]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.